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background: The humanized monoclonal antibody of bevacizumab directs against vascular endothelial growth factor and constitutes a well-
established treatment in various cancers. The process of angiogenesis interferes via several pathophysiological processes in the myocardium and the 
peripheral arteries. This prospective study evaluated the impact of bevacizumab on the arterial sclerosis.
methods: Twenty four patients treated for metastatic breast or colon cancer with combined chemotherapy including bevacizumab (n=12, 
bevacizumab group) or not including bevacizumab (n=12, control group) were evaluated. The arterial sclerosis of the patients was estimated by 
carotid-femoral Pulse Wave Velocity (c-fPWV) at baseline, at the middle of the initiation of the therapy (12 weeks), at the end of the therapy (24 
weeks) and at 6 months after the end of the therapy.
results: Values of arterial blood pressure had no significant difference between measurements. In bevacizumab group, c-fPWV was significantly 
higher at 12 weeks (9.16±2.32 versus 9.46±2.54 m/s, p=0.034), and at 24 weeks (9.16±2.32 versus 9.82±2.95 m/s, p=0.026) compared to 
baseline values. Furthermore, c-fPWV remained higher 6 months after the end of the therapy (9.16±2.32 versus 9.96±2.88 m/s, p=0.016). In control 
group, there was no significant difference between the measurements at 12 weeks of treatment (8.56±2.26 versus 8.41±2.10 m/s, p=0.296), at 
24 weeks (8.56±2.26 versus 8.54±2.28 m/s, p=0.785), and at 6 months after the end of treatment (8.56±2.26 versus 8.48±2.23 m/s, p=0.482). 
Carotid- femoral Pulse Wave Velocity was positively related to therapy with bevacizumab in all phases of the follow-up.
conclusions: The angiogenesis inhibitor of bevacizumab has a direct effect on arterial sclerosis. Thus, neovasculirazation may play a role in the 
functional properties of peripheral arteries.
